Nuclide Therapeutics Leverages Enamine's Deep Expertise in Rapid and Scalable Synthesis of Small Molecules
Frankfurt, Germany / London, United Kingdom / Kyiv, Ukraine, 2 April 2026 – Nuclide Therapeutics and Enamine initiated their cooperation in 2025. Since then, Enamine has supported Nuclide Therapeutics in progressing from preclinical evaluation towards IND-enabling studies and first-in-human clinical trials for its lead program focused on first-in-class molecular radiotherapies for therapy-resistant cancers. The relationship proved to be highly productive and innovative, delivering development milestones ahead of schedule with short development cycles and efficient use of resources.
Nuclide Therapeutics is committed to advancing a new generation of precision radiotheranostics specifically designed to overcome resistance to current cancer therapies. The collaboration between the two companies has enabled to accelerate key aspects of Nuclide Therapeutics’ preclinical development through Enamine`s strong expertise in synthetic chemistry. Enamine`s ability to deliver high-quality materials within compressed timelines has been instrumental in supporting Nuclide Therapeutics' radiochemistry activities and progressing their program towards IND-enabling studies and first-in-human evaluation.
Enamine’s deep understanding of chemical space is reflected in its REAL Space, the world’s largest and most trusted collection of make-on-demand small molecules, capturing a significant share of synthetically accessible chemical space. REAL Compounds are readily synthesised through validated parallel synthesis protocols using qualified in stock building blocks.
In combination with its integrated capabilities in medicinal chemistry, synthetic chemistry, route scouting, and scale-up, alongside optimized R&D logistics, Enamine enables rapid design-make-test-analyse (DMTA) cycles and efficient production of small molecules within short timelines. Enamine Germany, based in Frankfurt, provides strong support in project coordination, rapid development, and scale-up activities.
Richard Edwards, Co-Founder & CTO of Nuclide Therapeutics: Our experience working with Enamine has been extremely positive. Their strength in synthetic chemistry, route scouting, and efficient scale-up has allowed us to rapidly access critical precursors and final compounds at the quality and quantities required for our program. The team has consistently delivered under tight timelines, with excellent project management and clear communication throughout. Enamine has been a highly responsive and collaborative partner, with the added benefit of close interaction with their teams in Kyiv and Frankfurt. Overall, the productivity, reliability, and quality of output have been outstanding.
Sven Wagner, PhD, Vice President of Partnerships at Enamine: We are very glad that Enamine has the opportunity, with its know-how and execution, to support Nuclide Therapeutics, meaningful and without delay, in the advancement of their pioneering radiotheranostic program towards first-in-human studies for the treatment of resistant tumours where existing cancer therapies provide no medication. Together, we have demonstrated an exceptionally cooperative and agile team of experts supporting the highly patient-centric focus of Nuclide Therapeutics. This successful cooperation exemplifies that Enamine accelerates the transition of small molecule candidates in preclinical development with rapid route scouting and upscaling at desired specifications.